Sichuan Kelun Pharmaceutical Co Ltd (002422 SHE) stock market data APIs
¥36.6044
-0.91(-2.5%)
as of July 1, 2025
Try our APIs with
free plan!
Sichuan Kelun Pharmaceutical Co Ltd Financial Data Overview
Price chart is built with
Anychart
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers infusion products; oral medication and other dosage form; plastic ampoule and powder liquid dual chamber infusion bag; medical devices, such as infusion set, injection syringes, detained needles, nebulizer, and blood sampling; and over-the-counter products. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Prev. Close
36.6044
Open
35.6906
High
36.1839
Low
35.4964
52 wk Range
22.0182-38.76
Market Cap
58 297 M
P/E Ratio
23.3846
Shares Outstanding
1 598 M
Revenue
19 983 M
EPS
0.29
Dividends (Yield)
0.0212
Beta
-0.01
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sichuan Kelun Pharmaceutical Co Ltd data using free add-ons & libraries
Get Sichuan Kelun Pharmaceutical Co Ltd Fundamental Data
Sichuan Kelun Pharmaceutical Co Ltd Fundamental data includes:
- Net Revenue: 19 983 M
- EBITDA: 4 413 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-23
- EPS/Forecast: 0.41
Get Sichuan Kelun Pharmaceutical Co Ltd End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sichuan Kelun Pharmaceutical Co Ltd News
New
Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors
CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the investig...
Merck discontinues some cancer drug development with China's Sichuan Kelun
By Andrew Silver SHANGHAI, Oct 23 (Reuters) - Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs w...
Merck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3 billion
Merck & Co. Inc. said Thursday that it entered into an agreement with Sichuan Kelun Pharmaceutical Co. Ltd. to develop seven new cancer therapies. Merck will pay the Chinse biotech an upfront payment ...
Kamada to Present at the Jefferies Global Plasma Summit
REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will pre...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
